Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02032823) enrolled 1,836 people in total — 921 received olaparib (a tablet-based medicine) and 915 received a placebo (a dummy pill with no active ingredient). The trial was measuring outcomes in people with a type of breast cancer linked to certain inherited gene changes (BRCA mutations), after they had already completed chemotherapy and surgery. The main thing the trial tracked was "invasive disease-free survival," which means how many people experienced their cancer coming back, a new cancer developing, or death during the study period. Several secondary (additional) outcomes were also measured, including whether cancer spread to distant parts of the body, overall survival (deaths from any cause), new cancers in other areas, and how tired participants reported feeling over time. The reported data shows that for the main outcome — counting people who had a cancer recurrence, new cancer, or died — 106 events occurred in the olaparib group compared with 178 in the placebo group. For cancer spreading to distant parts of the body, 89 events were recorded in the olaparib group versus 152 in the placebo group. For deaths from any cause, 75 occurred in the olaparib group compared with 109 in the placebo group. Regarding new cancers developing in other locations (such as the opposite breast or the ovaries), the numbers were generally small and similar or slightly lower in the olaparib group compared with the placebo group. For tiredness (measured using a standard questionnaire scored from 0 to 52, where a higher score means less fatigue), the reported data shows that scores changed only slightly from the starting point in both groups across all time points measured, with no large differences between the two groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Breast Cancer Trial, Active, Not Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with breast cancer that has not spread to other parts of the body, and the cancer has been confirmed by a tissue sample (biopsy).
- Your breast cancer is either "triple negative" (meaning it does not respond to certain hormone or targeted therapies) or hormone receptor-positive but HER2-negative (a specific type based on lab tests).
- You carry an inherited gene change (mutation) in either the BRCA1 or BRCA2 gene that is known or expected to be harmful.
- You have already had appropriate surgery on your breast and underarm lymph nodes.
- You have completed at least 6 cycles of chemotherapy (either before or after surgery) using drugs from the anthracycline or taxane families, or both; previous platinum-based chemotherapy for breast or other cancers (such as ovarian) is also allowed.
- You are in generally good physical health and able to carry out daily activities with little or no limitation (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously been treated with a type of drug called a PARP inhibitor (such as olaparib), or you have a known allergy to the ingredients in the study treatment.
- You have been diagnosed with another cancer, unless it is certain limited exceptions such as: non-melanoma skin cancer that was fully treated, cervical cancer in situ that was cured, non-invasive breast cancer (DCIS), or a very early-stage womb cancer; or another solid cancer or lymphoma diagnosed at least 5 years ago, fully treated with no signs of return, and treated with no more than one course of chemotherapy.
- You are currently taking certain medicines that strongly or moderately interfere with how the study drug is processed by your body — this includes some antifungals, antibiotics, heart medications, and HIV treatments, among others (confirm with trial site for your specific medications); a waiting period of 2–5 weeks off these medicines may be required before joining.
- You are currently taking certain other medicines that speed up the breakdown of the study drug in your body, such as some epilepsy medications, tuberculosis drugs, or St John's Wort (a herbal supplement); a waiting period of 3–5 weeks off these medicines may be required before joining.
- Your breast cancer has spread to other parts of your body (metastatic disease).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 15 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Invasive Disease Free Survival (IDFS)
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.